

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/051,307	01/22/2002	Ziyu Dai	059440-0141	4790
22428	7590 07/01/2004		EXAMINER	
FOLEY AND LARDNER			FOX, DAVID T	
SUITE 500 3000 K STREET NW			ART UNIT	PAPER NUMBER
WASHINGTON, DC 20007			1638	
			DATE MAILED: 07/01/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>	Application No.	Applicant(s)			
•	10/051,307	DAI ET AL.			
Office Action Summary	Examiner	Art Unit			
,		1638			
The MAILING DATE of this communication app	David T. Fox ears on the cover sheet with the				
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1) Responsive to communication(s) filed on	_•				
2a) This action is <b>FINAL</b> . 2b) This	This action is <b>FINAL</b> . 2b) This action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)					
Application Papers					
9) The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)	<b></b>	(575.446)			
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)	4)  Interview Summ Paper No(s)/Ma	il Date			
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Inform 6) Other:	al Patent Application (PTO-152)			
LS. Patent and Trademark Office					

Application/Control Number: 10/051,307

Art Unit: 1638

Restriction to one of the following inventions is required under 35 U.S.C.

121:

- I. Claims 1-2, 5, 7, 9, 11-12 and 16, drawn to a pin1 promoter, expression cassettes comprising it operably linked to a heterologous coding sequence, plant cells and plants transformed therewith, and methods of its use to transform plants and express heterologous genes, classified in class 800, subclass 287, for example.
- II. Claims 3-4, 6, 8, 10 and 13-14, drawn to an amt promoter, expression cassettes comprising it operably linked to a heterologous coding sequence, plant cells and plants transformed therewith, and methods of its use to transform plants and express heterologous genes, classified in class 536, subclass 24.1, for example.
- III. Claim 15, drawn to a pin1 protein-coding sequence, classified in class 536, subclass 23.6, for example.
- IV. Claim 17, drawn to an amt protein-coding sequence, classified in class 435, subclass 69.1, for example.

The inventions are distinct, each from the other because:

Inventions I-IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04,

Application/Control Number: 10/051,307

Art Unit: 1638

MPEP § 808.01). In the instant case the different inventions have different modes of operation and different functions.

Each invention involves biochemically and physiologically divergent starting materials and processes not required by the other.

Group I involves pin1 promoters not required by any other Group. Group II involves amt promoters not required by any other group.

Groups I and II require non-pin1 and non-amt protein-encoding sequences, expression vectors, methods for plant transformation and regeneration, and the resultant transformed plant cells and plants, each not required by Groups III and IV.

Group III involves a pin1 protein-encoding sequence, not required by any other group.

Group IV involves an amt protein-encoding sequence, not required by any other group.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, classification, and fields of search, restriction for examination purposes as indicated is proper.

Applicants are reminded that nucleotide sequences encoding different proteins or comprising different promoter sequences are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such

Art Unit: 1638

nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq.

Upon election of Group I or II above, Applicant is additionally required to select a single nucleotide sequence for said Group. This requirement is not to be construed as a requirement for an election of species, since each nucleotide sequence is not a member of single genus of invention, but constitutes an independent and patentably distinct invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David T. Fox whose telephone number is (571) 272-0795. The examiner can normally be reached on Monday through Friday from 10:30AM to 7:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached on (571) 272-0804. The fax phone number for this Group is (703) 872-9306.

June 25, 2004

DAVID T. FOX PRIMARY EXAMINER

GROUP 180 1638